Quick Answer
Stoke Therapeutics, Inc. reported Operating Income of -$20.59 million for fiscal year 2025.
Stoke Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$20.59M | +79.7% |
| 2024 | -$101.37M | +11.7% |
| 2023 | -$114.77M | -10.0% |
| 2022 | -$104.36M | -21.3% |
| 2021 | -$86.06M | -62.3% |
| 2020 | -$53.04M | -48.7% |
| 2019 | -$35.68M | -179.1% |
| 2018 | -$12.78M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$43.09M | -43.6% | -57.8% |
| June 30, 2025 | -$27.30M | +7.0% | -124.5% |
| March 31, 2025 | $111.24M | +492.1% | +470.8% |
| September 30, 2024 | -$30.00M | -10.2% | -2.3% |
| June 30, 2024 | -$29.34M | +11.8% | -3.4% |
| March 31, 2024 | -$28.37M | -14.9% | -4.2% |
| September 30, 2023 | -$27.23M | -0.3% | +18.1% |
| June 30, 2023 | -$33.26M | -31.8% | -34.7% |
- Stoke Therapeutics, Inc. showed an increase of +79.7% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Stoke Therapeutics, Inc.’s operating income has declined by 61.1% (from -$12.78 million to -$20.59 million).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: